Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Gregory M. Botting"'
Autor:
Palak R, Parekh, Gregory M, Botting, Denise B, Thurber, Marika, Boruszczak, William, Murphy, Greg P, Bertenshaw
Publikováno v:
Tumor Biology. 44:249-267
BACKGROUND: Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths. Current companion diagnostics use driver mutation sequencing to select patients for molecularly targeted agents (MTA), even though most patients lack actionable mutat
Autor:
Bertenshaw Greg P, Gregory M Botting, Jennifer A Brichetti, Senthamil R. Selvan, Denise B Thurber
Publikováno v:
Cancer biotherapyradiopharmaceuticals.
Background: Cetuximab, an epidermal growth factor receptor (EGFR)-targeting antibody, remains the only Food and Drug Administration-approved targeted therapy for squamous cell carcinoma (SCC) of head and neck/esophagus. However, in clinical trials, c
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0136155 (2015)
Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when administered individually or in combination to non-small cell lung cancer (NSCLC) patients. However, the overall efficacies of TKIs are limited due to the developme
Externí odkaz:
https://doaj.org/article/7ac452d0822f4c48aa652de7a9f35718
Autor:
Jason T Fong, Ryan J Jacobs, David N Moravec, Srijayaprakash B Uppada, Gregory M Botting, Marie Nlend, Neelu Puri
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e78398 (2013)
The use of tyrosine kinase inhibitors (TKIs) against EGFR/c-Met in non-small cell lung cancer (NSCLC) has been shown to be effective in increasing patient progression free survival (PFS), but their efficacy is limited due to the development of resist
Externí odkaz:
https://doaj.org/article/86457fa152f34fee92dd43a8e668c4b6
Autor:
Zechary Rios, Luke Wojdyla, Neelu Puri, Srijayaprakash B. Uppada, Caleb Shearrow, Amanda L Stone, Joseph T. Devito, Gregory M. Botting, Zachary Crees, Kymberly Harrington, Jennifer Girard
Publikováno v:
Current Pharmaceutical Design. 20:6422-6437
Cancer is a leading cause of death worldwide and an estimated 1 in 4 deaths in the United States is due to cancer. Despite recent advances in cancer treatment, adverse effects related to cancer therapy remain a limiting factor for many patients. The
Autor:
Ceyda Bertram, Jennifer Girard, Manohar Reddy Shambannagari, David N Moravec, Ryan J. Jacobs, Srijayaprakash B. Uppada, Neelu Puri, Gregory M. Botting, Deven Etnyre, Amanda L Stone, Jason T. Fong, Zachary Crees, Supriya Rajanna
Publikováno v:
Cancer Biology & Therapy
Numerous tyrosine kinase inhibitors (TKIs) targeting c-Met are currently in clinical trials for several cancers. Their efficacy is limited due to the development of resistance. The present study aims to elucidate this mechanism of c-Met TKI resistanc
Autor:
Neelu Puri, Marie Nlend, Jason T. Fong, Gregory M. Botting, David N Moravec, Ryan J. Jacobs, Srijayaprakash B. Uppada
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 11, p e78398 (2013)
PLoS ONE, Vol 8, Iss 11, p e78398 (2013)
The use of tyrosine kinase inhibitors (TKIs) against EGFR/c-Met in non-small cell lung cancer (NSCLC) has been shown to be effective in increasing patient progression free survival (PFS), but their efficacy is limited due to the development of resist
Autor:
Brad Foster, Gagan Chhabra, Brian Webb, Marie Nlend, Ichwaku Rastogi, Tsatsral Iderzorig, Andrew Webb, Gregory M. Botting, Neelu Puri
Publikováno v:
Cancer Research. 76:1599-1599
NSCLC cells acquire resistance to EGFR and c-Met TKIs after prolonged use. Our studies indicate that resistance maybe due to upregulation of alternative signaling pathways such as Wnt and mTOR. We have found that activation of Wnt/β-Catenin is also
Autor:
Luke Wojdyla, Zechary Rios, Ceyda Bertram, Caleb Shearrow, Srijayaprakash B. Uppada, Gregory M. Botting, Neelu Puri
Publikováno v:
Journal of Postgenomics Drug & Biomarker Development.
Traditional chemotherapy is the first treatment option for the majority of cancer patients, but due to harsh and toxic side effects, more targeted therapies are needed. T-oligo is an oligonucleotide homologous to the 3’ overhang of the telomere. It
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0136155 (2015)
PLoS ONE
PLoS ONE
Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when administered individually or in combination to non-small cell lung cancer (NSCLC) patients. However, the overall efficacies of TKIs are limited due to the developme